Trials / Completed
CompletedNCT03291379
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
VEROnA: A Window of Opportunity Study of Vandetanib-eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
Detailed description
A pilot open-label single arm multicenter phase 0 window of opportunity study of BTG-002814 given up to 3 weeks prior to surgery in up to 12 patients with resectable Hepatocellular carcinoma (HCC) or Colorectal cancer (CRC) with liver metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BTG-002814 | BTG-002814 containing 100 mg vandetanib |
Timeline
- Start date
- 2017-05-17
- Primary completion
- 2019-08-03
- Completion
- 2019-08-03
- First posted
- 2017-09-25
- Last updated
- 2021-07-19
- Results posted
- 2021-02-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03291379. Inclusion in this directory is not an endorsement.